Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Calcitonin gene-related peptide-targeting drugs and Raynaud’s phenomenon: a real-world potential safety signal from the WHO pharmacovigilance database
Alexandre O. Gérard, Diane Merino, Elise K. Van Obberghen, et al.
The Journal of Headache and Pain (2022) Vol. 23, Iss. 1
Open Access | Times Cited: 33

Showing 1-25 of 33 citing articles:

CGRP physiology, pharmacology, and therapeutic targets: migraine and beyond
Andrew F. Russo, Debbie L. Hay
Physiological Reviews (2022) Vol. 103, Iss. 2, pp. 1565-1644
Open Access | Times Cited: 162
Hallmarks of primary headache: part 1 – migraine
Alberto Raggi, Matilde Leonardi, Marco A. Arruda, et al.
The Journal of Headache and Pain (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 27
Monoclonal Antibodies against Calcitonin Gene-Related Peptide for Migraine Prophylaxis: A Systematic Review of Real-World Data
Antun R. Pavelić, Christian Wöber, Franz Riederer, et al.
Cells (2022) Vol. 12, Iss. 1, pp. 143-143
Open Access | Times Cited: 38
Mode and site of action of therapies targeting CGRP signaling
Alejandro Labastida‐Ramírez, Edoardo Caronna, Cédric Gollion, et al.
The Journal of Headache and Pain (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 33
Adverse event reporting of four anti-Calcitonin gene-related peptide monoclonal antibodies for migraine prevention: a real-world study based on the FDA adverse event reporting system
Wenfang Sun, Yali Li, Binbin Xia, et al.
Frontiers in Pharmacology (2024) Vol. 14
Open Access | Times Cited: 11
Chilblains after galcanezumab for chronic migraine prevention: A case report
Lakshini Gunasekera, Jason C. Ray
Cephalalgia Reports (2025) Vol. 8
Open Access | Times Cited: 1
Ten open questions in migraine prophylaxis with monoclonal antibodies blocking the calcitonin-gene related peptide pathway: a narrative review
Jean Schoenen, Annelies Van Dycke, Jan Versijpt, et al.
The Journal of Headache and Pain (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 17
Cardiovascular Adverse Drug Reactions of Anti-Calcitonin Gene-Related Peptide Monoclonal Antibodies for Migraine Prevention: An Analysis from the European Spontaneous Adverse Event Reporting System
Emanuela Elisa Sorbara, María Antonietta Barbieri, Giulia Russo, et al.
BioDrugs (2024) Vol. 38, Iss. 2, pp. 275-285
Closed Access | Times Cited: 6
Drug-induced cardiac toxicity and adverse drug reactions, a narrative review
Alexandre Destère, Diane Merino, Thibaud Lavrut, et al.
Therapies (2023) Vol. 79, Iss. 2, pp. 161-172
Closed Access | Times Cited: 12
Emerging drugs for the preventive treatment of migraine: a review of CGRP monoclonal antibodies and gepants trials
Marcello Silvestro, Ilaria Orologio, Mattia Siciliano, et al.
Expert Opinion on Emerging Drugs (2023) Vol. 28, Iss. 2, pp. 79-96
Closed Access | Times Cited: 11
Adverse event profile of CGRP monoclonal antibodies: findings from the FDA adverse event reporting database
Qi Wang, Jingfang Liu, Hao Sun, et al.
Expert Opinion on Drug Safety (2023) Vol. 23, Iss. 1, pp. 107-117
Open Access | Times Cited: 11
Migraine Management in Medically Complex Patients: a Narrative Review
Megan A. Hird, Claire H. Sandoe
Current Neurology and Neuroscience Reports (2024) Vol. 24, Iss. 9, pp. 423-438
Closed Access | Times Cited: 4
Cardiovascular Safety of Anti-CGRP Monoclonal Antibodies in Older Adults or Adults With Disability With Migraine
Seonkyeong Yang, Yulia Orlova, Haesuk Park, et al.
JAMA Neurology (2025)
Closed Access
Disproportionality analysis of Raynaud’s phenomenon associated with calcitonin gene-related peptide inhibitors using the Food and Drug Administration adverse event reporting system
Nai Lee, Ji Hoon Ok, Su‐jin Rhee, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Chilblains with CGRP monoclonal antibody treatment of chronic migraine: A case report and literature review
Bradley Torphy, Melody Smith, C. Medrano, et al.
Cephalalgia Reports (2025) Vol. 8
Open Access
A Brief Review of Gepants
Diana Li, Jessica Abreu, Stewart J. Tepper
Current Pain and Headache Reports (2023) Vol. 27, Iss. 9, pp. 479-488
Closed Access | Times Cited: 10
Ubrogepant and rimegepant: signal detection using spontaneous reports of adverse events from the Food and Drug Administration Adverse Event Reporting System
Vera Battini, Carla Carnovale, Emilio Clementi, et al.
Expert Opinion on Drug Safety (2023) Vol. 22, Iss. 11, pp. 1105-1112
Closed Access | Times Cited: 9
Myocardial infarction associated with erenumab: A case report
Justine Perino, Virginie Corand, Elise Laurent, et al.
Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy (2022) Vol. 42, Iss. 7, pp. 585-589
Open Access | Times Cited: 16
Migraine and the Gender Divide
Aimen Vanood, India Rangel, Amaal J. Starling
Neurologic Clinics (2023) Vol. 41, Iss. 2, pp. 231-247
Closed Access | Times Cited: 9
A Review of Calcitonin Gene-Related Peptide and Its Implications for Vestibular Disorders
R L Baron, Kristen K. Steenerson
Current Treatment Options in Neurology (2024) Vol. 26, Iss. 6, pp. 203-228
Closed Access | Times Cited: 2
The Neuropsychiatric Safety Profile of Lasmiditan: A Comparative Disproportionality Analysis with Triptans
Diane Merino, Alexandre O. Gérard, Elise K. Van Obberghen, et al.
Neurotherapeutics (2023) Vol. 20, Iss. 5, pp. 1305-1315
Open Access | Times Cited: 5
Other Secondary Causes
Michael Hughes, Ami A. Shah
(2024), pp. 141-167
Closed Access | Times Cited: 1
Managing Cluster Headache in Patients with Medical, Psychiatric, and Surgical Comorbidities
Mark J. Burish, Alexander B. Guirguis, Emmanuelle A. D. Schindler
Current Neurology and Neuroscience Reports (2024) Vol. 24, Iss. 9, pp. 439-452
Closed Access | Times Cited: 1
Post-marketing safety concerns with rimegepant based on a pharmacovigilance study
Jialing Hu, Jing-Ying Wu, Shan Xu, et al.
The Journal of Headache and Pain (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 1
Systemic Vasospasm
Laura K. Hummers
(2024), pp. 193-206
Closed Access
Page 1 - Next Page

Scroll to top